-

05:27:23 AM

LUMO Stock News

LUMO - Lumos Pharma Inc

05/16/22 4:05 PM

Nasdaq : LUMO

conferenceslow float

Lumos Pharma to Participate in Upcoming Investor Conferences

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event: H.C. Wainwright 2022 Global

RHEA-AI

neutral

05/10/22 4:01 PM

Nasdaq : LUMO

earningsclinical triallow float

Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

Clinical Collaboration Initiated with Massachusetts General

RHEA-AI

neutral

05/05/22 9:00 AM

Nasdaq : LUMO

clinical triallow float

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare

RHEA-AI

neutral

04/26/22 9:00 AM

Nasdaq : LUMO

conferencesearningslow float

Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022. The company will host a conference call and webcast

RHEA-AI

neutral

04/11/22 8:30 AM

Nasdaq : LUMO

clinical triallow float

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases,

RHEA-AI

neutral

03/23/22 4:05 PM

Nasdaq : LUMO

conferenceslow float

Lumos Pharma to Participate in the Cantor Rare Disease Symposium

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel discussion

RHEA-AI

neutral

03/10/22 4:01 PM

Nasdaq : LUMO

earningslow float

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on

RHEA-AI

negative

03/10/22 9:00 AM

Nasdaq : LUMO

conferenceslow float

Lumos Pharma to Participate in Upcoming Investor Conferences

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34 th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in

RHEA-AI

neutral

02/23/22 9:00 AM

Nasdaq : LUMO

conferencesearningslow float

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022. The company

RHEA-AI

neutral

01/05/22 9:00 AM

Nasdaq : LUMO

conferenceslow float

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A

RHEA-AI

neutral

LUMO Data

IndustryPharmaceutical Preparation Manufacturing
Websitelumos-pharma.com
Security nameLumos Pharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees29
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Lumos Pharma Inc

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU.